Jan 2, 2019 · 26m · a16z
a16z Podcast | The Rise of the Digital 'Pill'
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this episode of the a16z Podcast, host Hannah and moderator Malinka Walaliate join industry experts Sean Duffy and Vijay Pande to explore how digital therapeutics are transforming healthcare into a software-driven discipline. The panel discusses clinical validation, patient engagement, commercialization challenges, and the future role of AI in scaling proactive care.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. How this is scored →
The host as informed peer 4.5 Guest teaching 4.1 Guest disagreement 1.6 The host pushing back 2.0
speaking balance: gold is the host, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 22:59 Gentle rejection of 'sick care' framing
Sean explicitly pushes back against Malinka's assertion that healthcare ignores prevention, calling it an oversimplification and citing existing preventive mechanisms like USPSTF guidelines and vaccines.
Hardest push from the host ▶ 10:12 Challenging digital health with AMA 'snake oil' quoteMalinka directly confronts the guests with skepticism from traditional healthcare, citing the head of the American Medical Association calling digital health technologies 'digital snake oil'.
Biggest teaching moment ▶ 22:59 Reframing the prevention paradigmSean educates the host on existing preventive care infrastructure such as USPSTF guidelines and explains that digital health intervenes primarily at tipping-point populations rather than zero-risk populations.
The host holds their own ▶ 8:45 Citing specific internal trial detailsMalinka demonstrates deep familiarity with the guest's domain by bringing up a specific Omada experiment where tweaking notification frequency directly improved clinical weight loss outcomes.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The host as informed peer | Guest teaching | Guest disagreement | The host pushing back | Why |
|---|---|---|---|---|---|---|
| The Third Wave of Therapeutics | 4 | 3 | 1 | 1 | Malinka frames the discussion effectively, synthesizing the guests' explanations of digital diagnostics and adjuncts into a clear 'third wave' framing. The guests provide foundational historical context around biologics without hostility. | |
| Behavioral Conditions and Scalable Software | 5 | 4 | 1 | 2 | Malinka asks sharp, targeted questions about measuring efficacy and head-to-head pharmaceutical comparisons. Vijay and Sean explain why digital therapeutics can match or exceed drug performance for behavioral conditions. | |
| Drivers of Adoption and Rapid Data-Driven Iteration | 6 | 3 | 1 | 1 | Malinka demonstrates high expertise by referencing a specific Omada experiment regarding notification frequency affecting patient outcomes. Sean elaborates on internal trial latency reduction and counterintuitive engagement data among seniors. | |
| Addressing Skepticism and the 'Digital Snake Oil' Label | 6 | 5 | 3 | 5 | Malinka presents a strong challenge by introducing the AMA chief's 'digital snake oil' remark. Sean deftly defends digital health by contextualizing the AMA's demand for rigorous peer-reviewed evidence. | |
| Human Connection Versus AI in Coaching | 4 | 4 | 2 | 3 | Malinka probes the potential loss of human connection in digital care and the role of AI coaching. Sean shares skepticism about near-term AI human replacements while Vijay highlights efficiency gains. | |
| Transforming Primary Care and Global Healthcare | 4 | 4 | 1 | 1 | Malinka directs the conversation toward structural questions on innovating inside versus outside existing healthcare systems. The guests offer broad context on physician shortages, leapfrogging in global markets like India, and augmenting doctor productivity. | |
| Commercialization, Reimbursement, and Value Generation | 3 | 4 | 1 | 1 | Malinka transitions into commercialization hurdles. Sean details working with P&T committees and setting up outcomes-based fee structures, while Vijay emphasizes customer ROI. | |
| Preventive Care and Value-Based Incentives | 4 | 6 | 3 | 2 | Malinka introduces the common premise that current healthcare ignores prevention in favor of 'sick care'. Sean gently rejects this premise as an oversimplification, pointing to vaccines, mammography, and official USPSTF guidelines. |
Statements from this episode (19)
Duffy: True digital health requires software to be the primary driver
“Most of the time people think of digital health where it's software driving, right? Software is leading the strategy, not a secondary, right? That's really the next generation of software in healthcare where software has to be a solution to make the big change…”
Pande: Digital therapeutics mirror the 1980s adoption curve of protein biologics
“In the eighties with the origin of biotech and protein biologics, we already went through, oh, you know, I know what a drug is. A drug's a small molecule. This protein thing, that's weird. I mean, the protein thing, that'll never be a drug. And you can list al…”
Pande: Digital therapeutics will majorly impact behavioral health conditions
“You know, when we think about this space, there are some things that I really imagine digital therapeutics making a huge impact in. Anything that's behavioral in nature. That when you talk about PTSD depression, anxiety, sleeping issues, and especially somethi…”
Duffy: Digital therapeutics software can scale reliably like traditional drugs
“Software and using a combination of social experiences, people, you know, devices, curriculum, content, you know, timelines, goals, all of that allows these approaches to Actually scale in a way that you might imagine a traditional drug could scale, where it's…”
Pande: Digital therapeutics can be evaluated with identical metrics to drugs
“There's a reason why digital therapeutics has a right to the term therapeutic, and in my mind it's because one can assess its efficacy in exactly the same way you would a drug.”
Duffy: Behavioral programs reduced diabetes risk better than drugs in trials
“In the original diabetes prevention program trial, they actually looked to see if these programs delivered in person would Be better than drugs that they hypothesized to work. And they were, you know, a program delivered far more efficacy in diabetes risk redu…”
Pande: Software will prove far more effective than small molecules for behavior
“I can imagine 10 years from now people would be like, well, what'd you expect? I mean, you wouldn't expect this small molecule that we didn't have like this Sense for how all of the human brain works and understanding behavior from a fomental molecular biologi…”
Duffy: Selling medications without digital companions will eventually be seen as laughable
“You could imagine that it would be viewed as laughable to not have a digital companion experience with a medicine.”
Duffy: Omada Health has amassed 11.5 million weight readings
“You look at what we've done, we've amassed about 11 and a half million weight readings. It's the largest longitudinal data set of these sorts of programs in the world.”
Pande: Digital therapeutics data moats outperform traditional pharmaceutical patents
“And you have an interesting barrier to entry that is far superior than something like patents.”
Duffy: Older patients engage and perform better in digital health programs
“It turns out that age, the older you are, the better you actually do, which is a little bit counterintuitive. You know, I think that it would be easy to think, well, digital, of course, young people are going to do it. Young people are going to do better, but …”
Pande: Digital therapeutics enable continuous, large-scale randomized clinical trials
“And instead on the digital therapeutic side, you can be running the equivalent RCTs of these randomized clinical trials all the time with super huge N. But that of course then puts the onus on, on, on those having digital therapeutics to make the case.”
Duffy: Digital health companies need peer-reviewed studies for clinical acceptance
“There will continue to be a need for evidence for evidence generation for digital health companies in a way that has traditionally been viewed as acceptable, which is peer reviewed publications. I mean, that's kind of the currency du jour of gaining clinical a…”
Duffy: Current AI cannot handle relationship-forward elements of healthcare
“Yet when you look at the majority of the complexity in scaling and all the challenges in building a business, a lot of it's very, very People forward and relationship forward. And it's all those kind of softer, kind of tougher elements that right now the world…”
Pande: AI will accelerate doctors long before replacing them
“And I think before we talk about replacing doctors at all, that doesn't make any sense when we could be accelerating them. Exactly. And having them do so much more. And I, I'm pretty sure we'll see that first. Just like you don't think a word processor with a …”
Pande: Developing countries will leapfrog the West in computational healthcare
“I can imagine leapfrogging in, in countries like this that don't have the infrastructure we have now, and that they would have an even greater benefit to moving quickly into this future.”
Duffy: Digital health companies are uniquely suited for outcome-based pricing models
“Prices on outcomes, I think digital companies are better equipped to do that because they're better able to measure their impact.”
Pande: Digital health startups must target cost and quality over general wellness
“People don't think enough about is also, is there going to be a huge ROI for your customers? And so, you know, you want to be able to ideally go after not just the wellness space, but something where you're having a really material impact on the cost of health…”